THE COST-EFFECTIVENESS OF PRECISION MEDICINE TREATMENT STRATEGIES FOR DIFFUSE LARGE B-CELL LYMPHOMA

OBJECTIVES: Diffuse large B cell lymphoma (DLBCL) is comprised of germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes; the latter is associated with worse survival with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) therapy. Preliminary...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-05, Vol.20 (5), p.A107
Hauptverfasser:	Chen, Q, Staton, AD, Ayer, T, Goldstein, DA, Koff, JL, Flowers, CR
Format:	Artikel
Sprache:	eng
Schlagworte:	Autografts B-cell lymphoma Chemotherapy Clinical medicine Clinical outcomes Clinical trials Cost analysis Cyclophosphamide Doxorubicin Health care expenditures Health status Lymphocytes B Lymphoma Medicare Monoclonal antibodies Precision medicine Prednisone Quality adjusted life years Rituximab Robustness Sensitivity analysis Simulation Subtypes Targeted cancer therapy Vincristine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!